2002: January: Alzheimer’s Research Papers
Scherder EJ, Deijen JB, Vreeswijk SH, Sergeant JA, Swaab DF. Cranial electrostimulation (CES) in patients with probable Alzheimer's disease. Behav Brain Res. 2002 Jan 22;128(2):215-7.
Vennerica A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport. 2002 Jan 21;13(1):83-7.
Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport. 2002 Jan 21;13(1):183-6.
Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, Tremp G, Pradier L, Brion JP. Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett. 2002 Jan 18;318(1):29-33.
Satoh K, Hata M, Yokota H. A novel member of the leucine-rich repeat superfamily induced in rat astrocytes by beta-amyloid. Biochem Biophys Res Commun. 2002 Jan 18;290(2):756-62.
Ilies M, Banciu MD, Ilies MA, Scozzafava A, Caproiu MT
Scozzafava A, Supuran CT. Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. J Med Chem. 2002 Jan 17;45(2):284-91.
Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA, MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002 Jan 16;287(3):329-36.
Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002 Jan 15;22(2):515-22.
Uryu K, Laurer H, McIntosh T, Praticò D, Martinez D, Leight S, Lee VM, Trojanowski JQ. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci. 2002 Jan 15;22(2):446-54. ,
Traynor K. NSAIDs may prevent Alzheimer's disease, study finds. Am J Health Syst Pharm. 2002 Jan 15;59(2):124.
Ostrakhovitch EA, Lordnejad MR, Schliess F, Sies H, Klotz LO. Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species. Arch Biochem Biophys. 2002 Jan 15;397(2):232-9.
Schöneich C. Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer's disease. Arch Biochem Biophys. 2002 Jan 15;397(2):370-6.
Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet. 2002 Jan 15;11(2):133-45.
Zareparsi S, Camicioli R, Sexton G, Bird T, Swanson P, Kaye J, Nutt J, Payami H. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet. 2002 Jan 15;107(2):156-61.
Krout KE, Jenkins JM, Loewy AD. High-resolution scanner for neuroanatomical analysis. J Neurosci Methods. 2002 Jan 15;113(1):37-40.
Nagy Z, Combrinck M, Budge M, McShane R. Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett. 2002 Jan 11;317(2):81-4. ,
Uryu S, Harada J, Hisamoto M, Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 2002 Jan 11;924(2):229-36.
Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002 Jan 11;924(2):133-40.
Myhre A, Tysnes OB. [Etiology and genetics of Alzheimer disease] Tidsskr Nor Laegeforen. 2002 Jan 10;122(1):50-3.
Kelz MB, Dent GW, Therianos S, Marciano PG, McIntosh TK, Coleman PD, Eberwine JH. Single-cell antisense RNA amplification and microarray analysis as a tool for studying neurological degeneration and restoration. Sci Aging Knowledge Environ. 2002 Jan 9;2002(1):re1.
Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002 Jan 8;58(1):62-70.
Nyenhuis DL, Gorelick PB, Freels S, Garron DC
Mateo I, Sánchez-Guerra M, Combarros O, Llorca J, Infante J, González-García J, del Molino JP, Berciano J. Lack of association between cathepsin D genetic polymorphism and Alzheimer disease in a Spanish sample. Am J Med Genet. 2002 Jan 8;114(1):31-3. ,
Yong W, Lomakin A, Kirkitadze MD, Teplow DB, Chen SH, Benedek GB. Structure determination of micelle-like intermediates in amyloid beta -protein fibril assembly by using small angle neutron scattering. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):150-4.
Sayeed A, Petrou M, Spyrou N, Kadyrov A, Spinks T. Diagnostic features of Alzheimer's disease extracted from PET sinograms. Phys Med Biol. 2002 Jan 7;47(1):137-48.
Richard E, Walstra GJ, van Campen J, Vissers E, van Gool WA. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy] Ned Tijdschr Geneeskd. 2002 Jan 5;146(1):24-7.
Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002 Jan 4;924(1):90-7.
Evans DB, Rank KB, Sharma SK.
Paley EL, Malinovskii V, Solomon B. SYNTHETIC PEPTIDE CORRESPONDING TO THE AMINO-TERMINAL REGION OF THE HUMAN TRYPTOPHANYL-tRNA SYNTHETASE, A COMPONENT OF ALZHEIMER'S DISEASE SPECIAL CONGOPHLIC PLAQUES AGGREGATES IN VITRO TO FORM AMYLOID-LIKE FIBRILS. ScientificWorldJournal. 2002 Jan 2;2(1 Suppl 2):117-8.
Eaker ED, Mickel SF, Chyou PH, Mueller-Rizner NJ
Rainville C, Marchand N, Passini R. Performances of patients with a dementia of the Alzheimer type in the Standardized Road-Map test of Direction Sense. Neuropsychologia. 2002;40(5):567-73.
Schneider JA, Bienias JL, Gilley DW, Kvarnberg DE, Mufson EJ, Bennett DA. Improved detection of substantia nigra pathology in Alzheimer's disease. J Histochem Cytochem. 2002 Jan;50(1):99-106.
Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol. 2002 Jan;51(1):125-8.
Leibing A. Flexible hips? On Alzheimer's disease and aging in Brazil. J Cross Cult Gerontol. 2002;17(3):213-32.
Henderson JN, Henderson LC. Cultural construction of disease: a "supernormal" construct of dementia in an American Indian tribe. J Cross Cult Gerontol. 2002;17(3):197-212.
Spada RS. Twenty-four-hour uniary cortisol levels in alzheimer disease and in dysthymia. Arch Gerontol Geriatr. 2002;35 Suppl:353-8.
Solfrizzi V. Serum apoliprotein E levels in alzheimer's disease and extreme longevity. Arch Gerontol Geriatr. 2002;35 Suppl:345-52.
Panza F. Lack of association between ace polymorphism and Alzheimer's disease in southern Italy. Arch Gerontol Geriatr. 2002;35 Suppl:239-45. ,
Lechiara MC. Plasma Abeta1-42 levels in Alzheimer's disease patients. Arch Gerontol Geriatr. 2002;35 Suppl:129-33.
Bergmann JM, Bertora GO. Cognitive disorders: diagnosis and treatment. Int Tinnitus J. 2002;8(2):104-7.
Jay V. Images in pathology: Alzheimer's disease. J Insur Med. 2002;34(2):127-30.
Pokorski RJ. Differentiating age-related memory loss from early dementia. J Insur Med. 2002;34(2):100-13.
Boda K, Kálmán J, Janka Z. Application of repeated measurement ANOVA models using SAS and SPSS: examination of the effect of intravenous lactate infusion in Alzheimer's disease. Stud Health Technol Inform. 2002;90:437-8.
Chan M, Campo E, Esteve D. Assessment of elderly mobility using a remote multisensor monitoring system. Stud Health Technol Inform. 2002;90:72-7.
Kodama N, Shimada T, Fukumoto I. Image-based diagnosis of Alzheimer-type dementia: measurements of hippocampal and ventricular areas in MR images. Magn Reson Med Sci. 2002;1(1):14-20.
Montgomery RJ, Karner TX, Kosloski K. Weighing the success of a national Alzheimer's disease service demonstration. J Aging Soc Policy. 2002;14(3-4):119-39.
Tappen RM, Williams CL, Barry C, Disesa D. Conversation Intervention with Alzheimer's Patients: Increasing the Relevance of Communication. Clin Gerontol. 2002;24(3-4):63-75.
Montgomery RJ, Karner TX, Kosloski K. Weighing the Success of a National Alzheimer's Disease Service Demonstration. J Aging Soc Policy. 2002;14(3/4):119-139.
Lehotsky J, Kaplán P, Murín R, Raeymaekers L. The role of plasma membrane Ca2+ pumps (PMCAs) in pathologies of mammalian cells. Front Biosci. 2002 Jan 1;7:d53-84.
Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, Lee KH, Kim SY, Han SH, Woo JI. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P47-53.
Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, Mayor PA, Michel JP, Giannakopoulos P. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry. 2002 Jan;159(1):82-7.
Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL, Purohit DP, Haroutunian V, Jones L. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry. 2002 Jan;159(1):59-65.
Togo T, Cookson N, Dickson DW. Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol. 2002 Jan;12(1):45-52.
Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 2002 Jan;12(1):21-35.
Kovács GG, Head MW, Hegyi I, Bunn TJ, Flicker H, Hainfellner JA, McCardle L, László L, Jarius C, Ironside JW, Budka H. Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol. 2002 Jan;12(1):1-11.
Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, Ichikawa M, Yamaguchi H, Takashima A. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci. 2002 Jan 1;22(1):133-41.
Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res. 2002 Jan 1;67(1):30-6.
Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu Rev Psychol. 2002;53:83-107.
Cui YH, Le Y, Gong W, Proost P, Van Damme J, Murphy WJ, Wang JM. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol. 2002 Jan 1;168(1):434-42.
Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002 Jan;143(1):205-12.
Peltékian E, Garcia L, Danos O. Neurotropism and retrograde axonal transport of a canine adenoviral vector: a tool for targeting key structures undergoing neurodegenerative processes. Mol Ther. 2002 Jan;5(1):25-32.
Podgorski CA, Lanning BD, Casaceli CJ, Nardi AL, Cox C. Dementia consults: predictors of compliance by primary care physicians. Am J Alzheimers Dis Other Demen. 2002 Jan-Feb;17(1):44-50.
Kertesz A, Munoz DG. Primary progressive aphasia: a review of the neurobiology of a common presentation of Pick complex. Am J Alzheimers Dis Other Demen. 2002 Jan-Feb;17(1):30-6.
Rogan S, Lippa CF. Alzheimer's disease and other dementias: a review. Am J Alzheimers Dis Other Demen. 2002 Jan-Feb;17(1):11-7.
Diehl J, Kurz A. [Frontotemporal dementia] Wien Med Wochenschr. 2002;152(3-4):92-7.
Schmidt R. [Vascular dementia] Wien Med Wochenschr. 2002;152(3-4):85-91.
Ransmayr G. [Dementia with Lewy bodies] Wien Med Wochenschr. 2002;152(3-4):81-4.
Förstl H. [Symptomatic therapy of Alzheimer dementia] Wien Med Wochenschr. 2002;152(3-4):77-80.
Kratzsch T, Peters J, Frölich L. [Etiology and pathogenesis of Alzheimer dementia] Wien Med Wochenschr. 2002;152(3-4):72-6.
Reischies FM, Wertenauer F. [Early diagnosis of dementia] Wien Med Wochenschr. 2002;152(3-4):66-71.
Fischer P, Bailer U, Hilger E, Leitner I. [Depressive pseudodementia] Wien Med Wochenschr. 2002;152(3-4):62-5.
Dal-Bianco P. [Differential diagnosis of dementia] Wien Med Wochenschr. 2002;152(3-4):57-61.
Rainer M, Krüger-Rainer C, Croy A. [Family caregiver help and self-help in Alzheimer dementia] Wien Med Wochenschr. 2002;152(3-4):107-12.
Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, Cutler NR. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet. 2002;41(3):225-34.
Hamann S, Monarch ES, Goldstein FC. Impaired fear conditioning in Alzheimer's disease. Neuropsychologia. 2002;40(8):1187-95.
Slavin MJ, Mattingley JB, Bradshaw JL, Storey E. Local-global processing in Alzheimer's disease: an examination of interference, inhibition and priming. Neuropsychologia. 2002;40(8):1173-86.
Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 2002;110(4):627-39.
Auquier P, Sapin C, Ziegler M, Tison F, Destée A, Dubois B, Allicar MP, Thibault JL, Jenkinson C, Peto V. [Validation of the French language version of the Parkinson's Disease Questionnaire - PDQ-39] Rev Neurol (Paris). 2002 Jan;158(1):41-9.
Yamaguchi S, Meguro K, Shimada M, Ishizaki J, Yamadori A, Sekita Y. Five-year retrospective changes in hippocampal atrophy and cognitive screening test performances in very mild Alzheimer's disease: the Tajiri Project. Neuroradiology. 2002 Jan;44(1):43-8.
Tedde A, Nacmias B, Cellini E, Bagnoli S, Sorbi S. Lack of association between NOS3 poly morphism and Italian sporadic and familial Alzheimer's disease. J Neurol. 2002 Jan;249(1):110-1. ,
Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002;110(2):199-211.
Diehl J, Kurz A. [Treatment of Alzheimer's disease. The status quo] Med Monatsschr Pharm. 2002 Jan;25(1):8-12.
Tilleman K, Stevens I, Spittaels K, Haute CV, Clerens S, Van Den Bergh G, Geerts H, Van Leuven F, Vandesande F, Moens L. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics. 2002 Jan;2(1):94-104.
Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H. p62 Is a Common Component of Cytoplasmic Inclusions in Protein Aggregation Diseases. Am J Pathol. 2002 Jan;160(1):255-63.
Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002 Jan;160(1):101-12.
Visser PJ, Verhey FR, Ponds RW, Jolles J. Characteristics of preclinical Alzheimer's disease. Int J Geriatr Psychiatry. 2002 Jan;17(1):88-9.
Dudley R, O'Brien J, Barnett N, McGuckin L, Britton P. Distinguishing depression from dementia in later life: a pilot study employing the Emotional Stroop task. Int J Geriatr Psychiatry. 2002 Jan;17(1):48-53.
Chow TW, Liu CK, Fuh JL, Leung VP, Tai CT, Chen LW, Wang SJ, Chiu HF, Lam LC, Chen QL, Cummings JL. Neuropsychiatric symptoms of Alzheimer's disease differ in Chinese and American patients. Int J Geriatr Psychiatry. 2002 Jan;17(1):22-8.
Scanlan JM, Brush M, Quijano C, Borson S. Comparing clock tests for dementia screening: naïve judgments vs formal systems--what is optimal? Int J Geriatr Psychiatry. 2002 Jan;17(1):14-21.
Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss WD, Ebmeier K. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med. 2002 Jan;43(1):21-6.
Golob EJ, Johnson JK, Starr A. Auditory event-related potentials during target detection are abnormal in mild cognitive impairment. Clin Neurophysiol. 2002 Jan;113(1):151-61.
Asbreuk CH, van Schaick HS, Cox JJ, Kromkamp M, Smidt MP, Burbach JP. The homeobox genes Lhx7 and Gbx1 are expressed in the basal forebrain cholinergic system. Neuroscience. 2002;109(2):287-98.
Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002 Jan;25(1):22-6.
Zheng H, Xu H, Uljon SN, Gross R, Hardy K, Gaynor J, Lafrancois J, Simpkins J, Refolo LM, Petanceska S, Wang R, Duff K. Modulation of A(beta) peptides by estrogen in mouse models. J Neurochem. 2002 Jan;80(1):191-6.
Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002 Jan;80(1):158-67.
Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem. 2002 Jan;80(1):91-100.
Barra V, Frenoux E, Boire JY. Automatic volumetric measurement of lateral ventricles on magnetic resonance images with correction of partial volume effects. J Magn Reson Imaging. 2002 Jan;15(1):16-22.
Panegyres PK, Zafiris-Toufexis K, Kakulas BA. The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease. J Neural Transm. 2002;109(1):77-89.
Smith JA, Knight RG. Memory processing in Alzheimer's disease. Neuropsychologia. 2002;40(6):666-82.
Keane J, Calder AJ, Hodges JR, Young AW. Face and emotion processing in frontal variant frontotemporal dementia. Neuropsychologia. 2002;40(6):655-65.
Nestor PJ, Graham KS, Bozeat S, Simons JS, Hodges JR. Memory consolidation and the hippocampus: further evidence from studies of autobiographical memory in semantic dementia and frontal variant frontotemporal dementia. Neuropsychologia. 2002;40(6):633-54.
Rusconi ML, Maravita A, Bottini G, Vallar G. Is the intact side really intact? Perseverative responses in patients with unilateral neglect: a productive manifestation. Neuropsychologia. 2002;40(6):594-604.
Petrella JR, Lustig C, Bucher LA, Jha AP, Doraiswamy PM. Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):112-3.
Rosen HJ, Kramer JH, Gorno-Tempini ML, Schuff N, Weiner M, Miller BL. Patterns of cerebral atrophy in primary progressive aphasia. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):89-97.
Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):81-8.
Burggren AC, Small GW, Sabb FW, Bookheimer SY. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):44-51.
Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.
Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002 Jan;59(1):102-12.
Romas SN, Santana V, Williamson J, Ciappa A, Lee JH, Rondon HZ, Estevez P, Lantigua R, Medrano M, Torres M, Stern Y, Tycko B, Mayeux R. Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch Neurol. 2002 Jan;59(1):87-91.
Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F, Di Luca M. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 2002 Jan;59(1):71-5. ,
Lopez OL, Becker JT, Kaufer DI, Hamilton RL, Sweet RA, Klunk W, DeKosky ST. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002 Jan;59(1):43-6.
Weiner MF, Tractenberg RE, Jin S, Gamst A, Thomas RG, Koss E, Thal LJ. Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications. J Psychiatr Res. 2002 Jan-Feb;36(1):19-25.
Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Björkhem I, von Bergmann K, Heun R. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002 Jan-Feb;36(1):27-32. ,
Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol. 2002 Jan;133(1):135-7.
Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci. 2002 Jan 1;22(1):10-20.
Yamaguchi N, Okada N, Sugiyama T. [Pharmacotherapy for the treatment of Alzheimer's disease--the present state and the development in the future] Nippon Rinsho. 2002 Jan;60(1):107-11.
Li CY, Sung FC, Wu SC. Risk of cognitive impairment in relation to elevated exposure to electromagnetic fields. J Occup Environ Med. 2002 Jan;44(1):66-72.
George JM. The synucleins. Genome Biol. 2002;3(1):REVIEWS3002.
Janka Z, Juhász A, Rimanóczy A A, Boda K, Márki-Zay J, Kálmán J. Codon 311 (Cys --> Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psychiatry. 2002;7(1):110-2. ,
Russ C, Lovestone S, Powell JF. Identification of genomic organisation, sequence variants and analysis of the role of the human dishevelled 1 gene in late onset Alzheimer's disease. Mol Psychiatry. 2002;7(1):104-9. ,
Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(1):32-43.
Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology. 2002;45(1):19-26.
Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47(1):64-70.
Cheng CY, Hong CJ, Liu HC, Liu TY, Tsai SJ. Study of the association between Alzheimer's disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes. Eur Neurol. 2002;47(1):26-9. ,
Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol Histopathol. 2002 Jan;17(1):273-88.
Takahashi RH, Nam EE, Edgar M, Gouras GK. Alzheimer beta-amyloid peptides: normal and abnormal localization. Histol Histopathol. 2002 Jan;17(1):239-46.
Seisser MA. 'New directions in Alzheimer's care' theme for 10th National Alzheimer's Disease Education Conference. J Healthc Qual. 2002 Jan-Feb;24(1):32-3.
Selhub J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging. 2002;6(1):39-42.
Smith JW, Al-Khamees O, Costall B, Naylor RJ, Smythe JW. Chronic aspirin ingestion improves spatial learning in adult and aged rats. Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):233-8.
Nakayama T, Sawada T. Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):119-38.
Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des. 2002;8(3):177-200.
Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Des. 2002;8(2):139-45.
Paganelli R, Di Iorio A, Patricelli L, Ripani F, Sparvieri E, Faricelli R, Iarlori C, Porreca E, Di Gioacchino M, Abate G. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp Gerontol. 2002 Jan-Mar;37(2-3):257-63.
Krasuski JS, Alexander GE, Horwitz B, Rapoport SI, Schapiro MB. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. Am J Psychiatry. 2002 Jan;159(1):74-81.
Watanabe Y, Fujiyama A, Ichiba Y, Hattori M, Yada T, Sakaki Y, Ikemura T. Chromosome-wide assessment of replication timing for human chromosomes 11q and 21q: disease-related genes in timing-switch regions. Hum Mol Genet. 2002 Jan 1;11(1):13-21.
Kalanj-Bognar S, Rundek T, Furac I, Demarin V, Cosovic C. Leukocyte lysosomal enzymes in Alzheimer's disease and Down's syndrome. J Gerontol A Biol Sci Med Sci. 2002 Jan;57(1):B16-21.
Hattori H, Matsumoto M, Iwai K, Tsuchiya H, Miyauchi E, Takasaki M, Kamino K, Munehira J, Kimura Y, Kawanishi K, Hoshino T, Murai H, Ogata H, Maruyama H, Yoshida H. The tau protein of oral epithelium increases in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2002 Jan;57(1):M64-70. ,
Xia M, Hyman BT. GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation-a role in Alzheimer's disease? J Neuroimmunol. 2002 Jan;122(1-2):55-64.
Wright JW, Kramár EA, Meighan SE, Harding JW. Extracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides. 2002 Jan;23(1):221-46.
Kurup RK, Kurup PA. Hypothalamic digoxin related membrane Na+-K+ ATPase inhibition and familial basal ganglia calcification. Neurosci Res. 2002 Jan;42(1):35-44.
Lamar M, Price CC, Davis KL, Kaplan E, Libon DJ. Capacity to maintain mental set in dementia. Neuropsychologia. 2002;40(4):435-45.
Padovan C, Versace R, Thomas-Antérion C, Laurent B. Evidence for a selective deficit in automatic activation of positive information in patients with Alzheimer's disease in an affective priming paradigm. Neuropsychologia. 2002;40(3):335-9.
Mayeux R, Lee JH, Romas SN, Mayo D, Santana V, Williamson J, Ciappa A, Rondon HZ, Estevez P, Lantigua R, Medrano M, Torres M, Stern Y, Tycko B, Knowles JA. Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. Am J Hum Genet. 2002 Jan;70(1):237-43.
Berger AK, Fahlander K, Wahlin A, Bäckman L. Negligible effects of depression on verbal and spatial performance in Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(1):1-7.
Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002;13(1):8-12.
Liu HC, Teng EL, Chuang YY, Lin KN, Fuh JL, Wang PN. The Alzheimer's Disease Assessment Scale: findings from a low-education population. Dement Geriatr Cogn Disord. 2002;13(1):21-6.
Jiménez-Escrig A, Fernandez-Lorente J, Herrero A, Baron M, Lousa M, de Blas G, Gobernado J. Event-related evoked potential P300 in frontotemporal dementia. Dement Geriatr Cogn Disord. 2002;13(1):27-32.
Selkoe DJ. Introducing transglutaminase into the study of Alzheimer's disease. A personal look back. Neurochem Int. 2002 Jan;40(1):13-6.
Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem Int. 2002 Jan;40(1):17-30.
Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int. 2002 Jan;40(1):69-78.
Kim SY, Jeitner TM, Steinert PM. Transglutaminases in disease. Neurochem Int. 2002 Jan;40(1):85-103.
Kabani NJ, Sled JG, Shuper A, Chertkow H. Regional magnetization transfer ratio changes in mild cognitive impairment. Magn Reson Med. 2002 Jan;47(1):143-8.
Levites Y, Youdim MB, Maor G, Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol. 2002 Jan 1;63(1):21-9.
Calingasan NY, Erdely HA, Anthony Altar C. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging. 2002 Jan-Feb;23(1):31-9.
Hoshino T, Kamino K, Matsumoto M. Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging. 2002 Jan-Feb;23(1):41-5.
Mórocz M, Kálmán J, Juhász A, Sinkó I, McGlynn AP, Downes CS, Janka Z, Raskó I. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging. 2002 Jan-Feb;23(1):47-53.
Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Almeida OP, Förstl H, Martins RN. Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment. Neurobiol Aging. 2002 Jan-Feb;23(1):55-8.
Van Everbroeck B, Dewulf E, Pals P, Lübke U, Martin JJ, Cras P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging. 2002 Jan-Feb;23(1):59-64.
Nijjar RK, Murphy C. Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiol Aging. 2002 Jan-Feb;23(1):65-73.
Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging. 2002 Jan-Feb;23(1):97-104.
Moretti R, Torre P, Antonello RM, Bisin Z, Relja G, Cazzato G, Bava A. Headache and Alzheimer's disease. Age Ageing. 2002 Jan;31(1):79-80.
Smith DS, Tsai LH. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol. 2002 Jan;12(1):28-36.
Hendriksen JV, Nottet HS, Smits HA. Secretases as targets for drug design in Alzheimer's disease. Eur J Clin Invest. 2002 Jan;32(1):60-8.
Whitehouse C, Chambers J, Howe K, Cobourne M, Sharpe P, Solomon E. NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube. Eur J Biochem. 2002 Jan;269(2):538-45.
Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agró A. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest. 2002 Jan;32(1):51-9.
Gutzmann H, Kühl KP, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry. 2002 Jan;35(1):12-8.
Gamliel A, Teicher C, Michaelson DM, Pradier L, Hartmann T, Beyreuther K, Stein R. Increased expression of presenilin 2 inhibits protein synthesis. Mol Cell Neurosci. 2002 Jan;19(1):111-24.
Ousset PJ, Viallard G, Puel M, Celsis P, Démonet JF, Cardebat D. Lexical therapy and episodic word learning in dementia of the Alzheimer type. Brain Lang. 2002 Jan;80(1):14-20.
Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, Bordiga G, DeCarli C, Laakso MP, Soininen H, Testa C, Zanetti O, Trabucchi M. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol. 2002 Jan;23(1):35-47.
Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002 Jan;23(1):27-32.
Blin M, Crusio WE, Hévor T, Cloix JF. Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice. Brain Res Bull. 2002 Jan 1;57(1):11-5.
Robles A, Del Ser T, Alom J, Peña-Casanova J, Grupo Asesor del Grupo de Neurologia de la Conducta y Demencias de la Sociedad Española de Neurología. [Proposal of criteria for clinical diagnosis of mild cognitive impairment, dementia and Alzheimer's disease] Neurologia. 2002 Jan;17(1):17-32.
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl). 2002 Jan;103(1):26-35.
Iida T, Furuta A, Nishioka K, Nakabeppu Y, Iwaki T. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol (Berl). 2002 Jan;103(1):20-5.
Lephart ED, West TW, Weber KS, Rhees RW, Setchell KD, Adlercreutz H, Lund TD. Neurobehavioral effects of dietary soy phytoestrogens. Neurotoxicol Teratol. 2002 Jan-Feb;24(1):5-16.
Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, Gennarelli M. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry. 2002;7(2):136-7. ,
Brendza RP, Bales KR, Paul SM, Holtzman DM. Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol Psychiatry. 2002;7(2):132-5.
Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2002 Jan;63(1):54-8.
Kemppainen N, Röyttä M, Collan Y, Ma SY, Hinkka S, Rinne JO. Unbiased morphological measurements show no neuronal loss in the substantia nigra in Alzheimer's disease. Acta Neuropathol (Berl). 2002 Jan;103(1):43-7.
Cannatà AP, Alberoni M, Franceschi M, Mariani C. Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(2):101-11.
Pélissier C, Roudier M, Boller F. Factorial validation of the Severe Impairment Battery for patients with Alzheimer's disease. A pilot study. Dement Geriatr Cogn Disord. 2002;13(2):95-100.
Tsai SJ, Liu HC, Liu TY, Cheng CY, Hong CJ. Association analysis for the genetic variants of the NMDA receptor subunit 2b and Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(2):91-4. ,
Rasmuson S, Näsman B, Carlström K, Olsson T. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(2):74-9.
Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(2):67-73.
Rich JB, Park NW, Dopkins S, Brandt J. What do Alzheimer's disease patients know about animals? It depends on task structure and presentation format. J Int Neuropsychol Soc. 2002 Jan;8(1):83-94.
Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc. 2002 Jan;8(1):58-71.
Leckey GS, Beatty WW. Predicting functional performance by patients with Alzheimer's disease using the Problems in Everyday Living (PEDL) Test: a preliminary study. J Int Neuropsychol Soc. 2002 Jan;8(1):48-57.
Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, Wirz-Justice A, Müller-Spahn F. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res. 2002 Jan;32(1):59-62.
Khotianov N, Singh R, Singh S. Lewy body dementia: case report and discussion. J Am Board Fam Pract. 2002 Jan-Feb;15(1):50-4.
Kurosinski P, Guggisberg M, Götz J. Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies? Trends Mol Med. 2002 Jan;8(1):3-5.
Thal DR, Ghebremedhin E, Haass C, Schultz C. UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain. Clin Neuropathol. 2002 Jan-Feb;21(1):35-40.
Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord. 2002;13(2):112-8. ,
Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des. 2002;8(3):201-13.
Nicolotti O, Pellegrini-Calace M, Altomar C, Carotti A, Carrieri A, Sanz F. Ligands of neuronal nicotinic acetylcholine receptor (nAChR): inferences from the Hansch and 3-D quantitative structure-activity relationship (QSAR) Models. Curr Med Chem. 2002 Jan;9(1):1-29.
Heese K, Nakayama T, Hata R, Masumura M, Akatsu H, Li F, Nagai Y, Yamamoto T, Kosaka K, Suemoto T, Sawada T. Characterizing CGI-94 (comparative gene identification-94) which is down-regulated in the hippocampus of early stage Alzheimer's disease brain. Eur J Neurosci. 2002 Jan;15(1):79-86.
Hüll M, Lieb K, Fiebich BL. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem. 2002 Jan;9(1):83-8.
Aschwanden C. Anti-inflammatory drugs slash Alzheimer risk. Bull World Health Organ. 2002;80(1):79.
Polleri A, Gianelli MV, Murialdo G. Dementia: a neuroendocrine perspective. J Endocrinol Invest. 2002 Jan;25(1):73-83.
Kozubski W, Swiderek M, Kloszewska I, Gwozdzinski K, Watala C. Blood platelet membrane fluidity and the exposition of membrane protein receptors in Alzheimer disease (AD) patients--preliminary Study. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):52-4.
Massoud F, Chertkow H, Whitehead V, Overbury O, Bergman H. Word-reading thresholds in Alzheimer disease and mild memory loss: a pilot study. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):31-9.
Carlson MC, Tschanz JT, Norton MC, Welsh-Bohmer K, Martin BK, Breitner JC. H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):24-30.
Rosen CS, Chow HC, Greenbaum MA, Finney JF, Moos RH, Sheikh JI, Yesavage JA. How well are clinicians following dementia practice guidelines? Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):15-23.
Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R. Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):8-14.
Edland SD, Tobe VO, Rieder MJ, Bowen JD, McCormick W, Teri L, Schellenberg GD, Larson EB, Nickerson DA, Kukull WA. Mitochondrial genetic variants and Alzheimer disease: a case-control study of the T4336C and G5460A variants. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):1-7.
Wang SY. Weight loss and metabolic changes in dementia. J Nutr Health Aging. 2002;6(3):131-5.
Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction. 2002 Jan;97(1):15-28.
Richartz E, Noda S, Schott K, Günthner A, Lewczuk P, Bartels M. Increased serum levels of CD95 in Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(3):178-82. ,
Luczywek E, Nowicka A, Pfeffer A, Czyzewski K, Styczynska M, Lalowski M, Barcikowska M. Cognitive deficits and polymorphism of apolipoprotein E in Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(3):171-7. ,
Järvenpää T, Rinne JO, Räihä I, Koskenvuo M, Löppönen M, Hinkka S, Kaprio J. Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord. 2002;13(3):149-55.
Londos E, Passant U, Risberg J, Gustafson L, Brun A. Contributions of other brain pathologies in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(3):130-48.
Kim KW, Jhoo JH, Lee JH, Lee DY, Lee KU, Youn JC, Youn JY, Woo JI. The domain-specific, stage-limited impact of the apolipoprotein E epsilon-4 allele on cognitive functions in Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(3):125-9.
Kim JM, Shin IS, Yoon JS. Apolipoprotein E among Korean Alzheimer's disease patients in community-dwelling and hospitalized elderly samples. Dement Geriatr Cogn Disord. 2002;13(3):119-24.
Desmond DW. Cognition and white matter lesions. Cerebrovasc Dis. 2002;13 Suppl 2:53-7.
Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis. 2002;13 Suppl 2:48-52.
Dorion AA, Sarazin M, Hasboun D, Hahn-Barma V, Dubois B, Zouaoui A, Marsault C, Duyme M. Relationship between attentional performance and corpus callosum morphometry in patients with Alzheimer's disease. Neuropsychologia. 2002;40(7):946-56.
Glosser G, Baker KM, de Vries JJ, Alavi A, Grossman M, Clark CM. Disturbed visual processing contributes to impaired reading in Alzheimer's disease. Neuropsychologia. 2002;40(7):902-9.
Moulin CJ, Perfect TJ, Conway MA, North AS, Jones RW, James N. Retrieval-induced forgetting in Alzheimer's disease. Neuropsychologia. 2002;40(7):862-7.
Cherry BJ, Buckwalter JG, Henderson VW. Better preservation of memory span relative to supraspan immediate recall in Alzheimer's disease. Neuropsychologia. 2002;40(7):846-52.
Andrés P, Van der Linden M. Are central executive functions working in patients with focal frontal lesions? Neuropsychologia. 2002;40(7):835-45.
Bochkov NP, Solov'eva DV, Strekalov DL, Khavinson VKh. [The role of molecular genetic diagnosis in prediction and prevention of age specific pathology] Klin Med (Mosk). 2002;80(2):4-8.
Campbell A. The potential role of aluminium in Alzheimer's disease. Nephrol Dial Transplant. 2002;17 Suppl 2:17-20.
Abrisqueta-Gomez J, Bueno OF, Oliveira MG, Bertolucci PH. Recognition memory for emotional pictures in Alzheimer's patients. Acta Neurol Scand. 2002 Jan;105(1):51-4.
Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S. THE PUBLIC HEALTH IMPACT OF ALZHEIMER'S DISEASE, 2000-2050: Potential Implication of Treatment Advances. Annu Rev Public Health. 2002;23:213-31.
Tsuji T, Shimohama S. Protein degradation in Alzheimer's disease and aging of the brain. Prog Mol Subcell Biol. 2002;29:43-60.
Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002;47(3):165-8.
Richardson JA, Burns DK. Mouse models of Alzheimer's disease: a quest for plaques and tangles. ILAR J. 2002;43(2):89-99.
Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med. 2002 Jan;40(1):2-8.
Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord. 2002;13(1):33-9.
Hogervorst E, Combrinck M, Lapuerta P, Rue J, Swales K, Budge M. The Hopkins Verbal Learning Test and screening for dementia. Dement Geriatr Cogn Disord. 2002;13(1):13-20.
Pappa H, Farrú R, Vilanova PO, Palacios M, Pizzorno MT. A new HPLC method to determine Donepezil hydrochloride in tablets. J Pharm Biomed Anal. 2002 Jan 1;27(1-2):177-82.
Marks SJ, Batra RR, Frishman WH. Estrogen replacement therapy for cognitive benefits: viable treatment or forgettable "senior moment"? Heart Dis. 2002 Jan-Feb;4(1):26-32.
Wang D, Chalk JB, Rose SE, de Zubicaray G, Cowin G, Galloway GJ, Barnes D, Spooner D, Doddrell DM, Semple J. MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer's disease and normal aging. Magn Reson Imaging. 2002 Jan;20(1):41-8.
Wang D, Doddrell DM. MR image-based measurement of rates of change in volumes of brain structures. Part I: method and validation. Magn Reson Imaging. 2002 Jan;20(1):27-40.
Knott V, Mohr E, Mahoney C, Engeland C, Ilivitsky V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. Neuropsychobiology. 2002;45(3):156-60.
Grunwald M, Busse F, Hensel A, Riedel-Heller S, Kruggel F, Arendt T, Wolf H, Gertz HJ. Theta-power differences in patients with mild cognitive impairment under rest condition and during haptic tasks. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):40-8.
Baddeley A, Wilson BA. Prose recall and amnesia: implications for the structure of working memory. Neuropsychologia. 2002;40(10):1737-43.
Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res. 2002 Jan 1;67(1):30-36.
Rusted J, Sheppard L. Action-based Memory in Alzheimer's Disease: a Longitudinal Look at Tea Making. Neurocase. 2002;8(1):111-26.
Riddoch MJ, Humphreys GW, Heslop J, Castermans E. Dissociations between Object Knowledge and Everyday Action. Neurocase. 2002;8(1):100-10.
Liu HC, Teng EL, Lin KN, Chuang YY, Wang PN, Fuh JL, Liu CY. Performance on the cognitive abilities screening instrument at different stages of Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(4):244-8.
Abel LA, Unverzagt F, Yee RD. Effects of stimulus predictability and interstimulus gap on saccades in Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(4):235-43.
Pettersson AF, Engardt M, Wahlund LO. Activity level and balance in subjects with mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(4):213-6.
Bronge L, Bogdanovic N, Wahlund LO. Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord. 2002;13(4):205-12.
Morley JE. The SAMP8 mouse: a model of Alzheimer disease? Biogerontology. 2002;3(1-2):57-60.
Dodd PR. Excited to death: different ways to lose your neurones. Biogerontology. 2002;3(1-2):51-6.
Wang J, Asensio VC, Campbell IL. Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. Curr Top Microbiol Immunol. 2002;265:23-48.
Colacicco AM, Panza F, Basile AM, Solfrizzi V, Capurso C, D'Introno A, Torres F, Capurso S, Cozza S, Flora R, Capurso A. F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer's Disease. Eur Neurol. 2002;47(4):209-13.
Munzar M, Levy S, Rush R, Averback P. Clinical study of a urinary competitve ELISA for neural thread protein in Alzheimer disease. Neurol Clin Neurophysiol. 2002;2002(1):2-8. ,
Olivieri G, Otten U, Meier F, Baysang G, Dimitriades-Schmutz B, Müller-Spahn F, Savaskan E. Oxidative Stress Modulates Tyrosine Kinase Receptor A and p75 Receptor (Low-Affinity Nerve Growth Factor Receptor) Expression in SHSY5Y Neuroblastoma Cells. Neurol Clin Neurophysiol. 2002;2002(2):2-10.
Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, Bonaiuto S, Perissinotto E, Scarlato G, Farchi G, Inzitari D, ILSA Working Group. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002 Jan;50(1):41-8.
Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 2002;1(2):125-35.
Soreghan B, Pike C, Kayed R, Tian W, Milton S, Cotman C, Glabe CG. The influence of the carboxyl terminus of the Alzheimer Abeta peptide on its conformation, aggregation, and neurotoxic properties. Neuromolecular Med. 2002;1(1):81-94.
Chan SL, Pedersen WA, Zhu H, Mattson MP. Numb modifies neuronal vulnerability to amyloid beta-peptide in an isoform-specific manner by a mechanism involving altered calcium homeostasis: implications for neuronal death in Alzheimer's disease. Neuromolecular Med. 2002;1(1):55-67.
Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med. 2002;1(1):1-31.
Bottini N, Bottini E, Gloria-Bottini F, Mustelin T. Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Ther Exp (Warsz). 2002;50(2):95-104.
Fukatsu R, Fujii M, Murakami S. [Psychiatric symptoms and pathological processes in patients with Alzheimer's disease--special reference to dissection analysis of the visual-spatial world] Seishin Shinkeigaku Zasshi. 2002;104(2):139-43.
Holzgrabe U. [Ibuprofen for Alzheimer's?] Pharm Unserer Zeit. 2002;31(2):130.
Bussière T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, Giannakopoulos P, Robakis NK, Morrison JH, Perl DP, Hof PR. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience. 2002;112(1):75-91.
Combrinck MI, Perry VH, Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience. 2002;112(1):7-11.
Vesey R, Birrell JM, Bolton C, Chipperfield RS, Blackwell AD, Dening TR, Sahakian BJ. Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention. CNS Drugs. 2002;16(7):485-500.
Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs. 2002;16(7):435-44.
Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS. 2002 Jan;110(1):88-98.
Rogers J, Lue LF, Walker DG, Yan SD, Stern D, Strohmeyer R, Kovelowski CJ. Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures. Ernst Schering Res Found Workshop. 2002;(39):25-44.
Hüll M, Hampel H. Neuroinflammation in Alzheimer's disease: potential targets for disease-modifying drugs. Ernst Schering Res Found Workshop. 2002;(39):159-78.
Pocock JM, Liddle AC, Hooper C, Taylor DL, Davenport CM, Morgan SC. Activated microglia in Alzheimer's disease and stroke. Ernst Schering Res Found Workshop. 2002;(39):105-32.
Anand R. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S33-9.
Altstiel LD. Barriers to Alzheimer disease drug discovery and development in the biotechnology industry. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S29-32.
Van Eldik LJ, Koppal T, Watterson DM. Barriers to Alzheimer disease drug discovery and development in academia. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S18-28.
Ferris SH. Clinical Trials in AD: Are Current Formats and Outcome Measures Adequate? Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S13-7.
Khachaturian ZS. Models and modeling systems in Alzheimer disease drug discovery. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S9-S12.
Fillit HM, O'Connell AW, Brown WM, Altstiel LD, Anand R, Collins K, Ferris SH, Khachaturian ZS, Kinoshita J, Van Eldik L, Dewey CF. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S1-8.
Sabaté R, Estelrich J. Aggregation characteristics of ovalbumin in beta-sheet conformation determined by spectroscopy. Biopolymers. 2002;67(2):113-20.
Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients (Cochrane Review). Cochrane Database Syst Rev. 2002;(2):CD003673.
Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2002;(2):CD003153.
Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R. Apolipoprotein E genotype and cognitive impairment in community-dwelling black older adults. Int J Psychiatry Med. 2002;32(1):55-67.
Hannesdóttir K, Snædal J. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population. Nord J Psychiatry. 2002;56(3):201-206.
Bronge L. Magnetic resonance imaging in dementia: a study of brain white matter changes. Acta Radiol Suppl. 2002;428:1-32.
Lema MJ. Emerging options with coxib therapy. Cleve Clin J Med. 2002;69 Suppl 1:SI76-84.
Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with lewy bodies. Drug Saf. 2002;25(7):511-23.
DeKroon RM, Armati PJ. The effects of oxidative stress and altered intracellular calcium levels on vesicular transport of apoe-egfp. Cell Biol Int. 2002;26(5):407-20.
Robert P. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin. 2002;18(3):156-71.
Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129-38.
Petersen KU. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions. Arzneimittelforschung. 2002;52(6):423-9.
Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng. 2002;4:155-74.
Kowalska A, Takahashi K, Kozubski W, Tabira T. Microtubule associated protein (tau) gene variability in patients with frontotemporal dementia. Folia Neuropathol. 2002;40(1):1-5.
Magni F, Galbusera C, Tremolada L, Ferrarese C, Kienle MG. Characterisation of adducts of the lipid peroxidation product 4-hydroxy-2-nonenal and amyloid beta-peptides by liquid chromatography/electrospray ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2002;16(15):1485-93.
Li JY, Henning Jensen P, Dahlström A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 2002;113(2):463-78.
Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S, Soininen H. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience. 2002;113(2):301-10.
Mattson MP. Involvement of superoxide in pathogenic action of mutations that cause Alzheimer's disease. Methods Enzymol. 2002;352:455-74.
Christen Y. [In Process Citation] J Soc Biol. 2002;196(1):85-94.
Buée L, Hamdane M, Delobel P, Sambo AV, Bégard S, Ghestem A, Sergeant N, Delacourte A. [In Process Citation] J Soc Biol. 2002;196(1):103-8.
Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2002;(3):CD003799.
Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2002;(3):CD001747.
Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane Review). Cochrane Database Syst Rev. 2002;(3):CD000207.
López-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;(3):CD000147.
Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet. 2002;3:67-99.
Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol. 2002;18:25-51.
Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with Galantamine in Sweden. Pharmacoeconomics. 2002;20(9):629-37.
Boller F, El Massioui F, Devouche E, Traykov L, Pomati S, Starkstein SE. Processing emotional information in Alzheimer's disease: effects on memory performance and neurophysiological correlates. Dement Geriatr Cogn Disord. 2002;14(2):104-12.
Barak Y, Aizenberg D. Suicide amongst Alzheimer's Disease Patients: A 10-Year Survey. Dement Geriatr Cogn Disord. 2002;14(2):101-3.
Ravaglia G, Forti P, Maioli F, Sacchetti L, Mariani E, Nativio V, Talerico T, Vettori C, Macini PL. Education, occupation, and prevalence of dementia: findings from the conselice study. Dement Geriatr Cogn Disord. 2002;14(2):90-100.
Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14(2):84-9.
MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the Risk of Dementia, Alzheimer's Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14(2):77-83.
Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord. 2002;14(2):64-76.
Müller-Thomsen T, Arlt S, Ganzer S, Mann U, Mass R, Naber D, Beisiegel U. Depression in Alzheimer's Disease Might Be Associated with Apolipoprotein E epsilon4 Allele Frequency in Women but Not in Men. Dement Geriatr Cogn Disord. 2002;14(2):59-63.
Caselli RJ, Beach TG, Sue LI, Connor DJ, Sabbagh MN. Progressive aphasia with lewy bodies. Dement Geriatr Cogn Disord. 2002;14(2):55-8.
Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res. 2002;136:467-86.
Ueda S, Sakakibara S, Watanabe E, Yoshimoto K, Koibuchi N. Vulnerability of monoaminergic neurons in the brainstem of the zitter rat in oxidative stress. Prog Brain Res. 2002;136:293-302.
Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging. 2002;19(6):405-27.
Hayes GM, Howlett DR, Griffin GE. Production of beta-amyloid by primary human foetal mixed brain cell cultures and its modulation by exogenous soluble beta-amyloid. Neuroscience. 2002;113(3):641-6.
Greenfield S, Vaux DJ. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism. Neuroscience. 2002;113(3):485-92.
Härtig W, Bauer A, Brauer K, Grosche J, Hortobágyi T, Penke B, Schliebs R, Harkany T. Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions? Rev Neurosci. 2002;13(2):95-165.
Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719-39.
Collen MF. Vicissitudes of preventive medicine and a new challenge. Methods Inf Med. 2002;41(3):224-9.
Pérez-Granados AM, Vaquero MP. Silicon, aluminium, arsenic and lithium: essentiality and human health implications. J Nutr Health Aging. 2002;6(2):154-62.
Olivieri G, Novakovic M, Savaskan E, Meier F, Baysang G, Brockhaus M, Müller-Spahn F. The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion. Neuroscience. 2002;113(4):849.
Bates KA, Fonte J, Robertson TA, Martins RN, Harvey AR. Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein. Neuroscience. 2002;113(4):785-96.
Vickers JC. A vaccine against Alzheimer's disease: developments to date. Drugs Aging. 2002;19(7):487-94.
Kozyrev KM, Siatkin SP, Berezov TT. [Morphological and biochemical features of cerebral beta-amyloidosis in long-livers] Vestn Ross Akad Med Nauk. 2002;(7):3-9.
Riemenschneider M, Schwarz S, Wagenpfeil S, Diehl J, Müller U, Förstl H, Kurz A. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E epsilon4 allele. Mol Psychiatry. 2002;7(7):782-5. ,
Taddei K, Fisher C, Laws SM, Martins G, Paton A, Clarnette RM, Chung C, Brooks WS, Hallmayer J, Miklossy J, Relkin N, St George-Hyslop PH, Gandy SE, Martins RN. Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Mol Psychiatry. 2002;7(7):776-81. ,
Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Hallmayer J, Almeida OP, Groth DM, Gandy SE, Förstl H, Martins RN. APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry. 2002;7(7):768-75.
Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(7):726-33.
Zajkowska JM, Hermanowska-Szpakowicz T. [In Process Citation] Przegl Epidemiol. 2002;56 Suppl 1:57-67.
El-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans. 2002;30(4):559-65.
Austen B, El-Agnaf O, Nagala S, Patel B, Gunasekera N, Lee M, Lelyveld V. Properties of neurotoxic peptides related to the BRI gene. Biochem Soc Trans. 2002;30(4):557-9.
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002;30(4):552-7.
Beher D, Shearman MS. gamma-Secretase inhibition. Biochem Soc Trans. 2002;30(4):534-7.
Hong L, Turner III RT, Koelsch G, Ghosh AK, Tang J. Memapsin 2 (beta-secretase) as a therapeutic target. Biochem Soc Trans. 2002;30(4):530-4.
Wolozin B. Cholesterol and Alzheimer's disease. Biochem Soc Trans. 2002;30(4):525-9.
Bruunsgaard H, Østergaard L, Andersen-Ranberg K, Jeune B, Pedersen BK. Proinflammatory cytokines, antibodies to Chlamydia pneumoniae and age-associated diseases in Danish centenarians: is there a link? Scand J Infect Dis. 2002;34(7):493-9.
Büchner M, Huber R, Sturchler-Pierrat C, Staufenbiel M, Riepe MW. Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. Neuroscience. 2002;114(2):285-9.
Tales A, Muir J, Bayer A, Snowden R. Spatial shifts in visual attention in normal ageing and dementia of the Alzheimer type. Neuropsychologia. 2002;40(12):2000.
Tales A, Butler S, Fossey J, Gilchrist I, Jones R, Troscianko T. Visual search in Alzheimer's disease: a deficiency in processing conjunctions of features. Neuropsychologia. 2002;40(12):1849.
Grace E, Rabiner C, Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience. 2002;114(1):265.
Zaidi N, Berezovska O, Choi E, Miller J, Chan H, Lilliehook C, Hyman B, Buxbaum J, Wasco W. Biochemical and immunocytochemical characterization of calsenilin in mouse brain. Neuroscience. 2002;114(1):247.
Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord. 2002;14(3):161-6.
Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S. Plasma Levels of Abeta42 and Abeta40 in Alzheimer Patients during Treatment with the Acetylcholinesterase Inhibitor Tacrine. Dement Geriatr Cogn Disord. 2002;14(3):156-60. ,
Svennerholm L, Bråne G, Karlsson I, Lekman A, Ramström I, Wikkelsö C. Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord. 2002;14(3):128-36.
Pirskanen M, Hiltunen M, Mannermaa A, Iivonen S, Helisalmi S, Lehtovirta M, Koivisto AM, Laakso M, Soininen H, Alafuzoff I. Interleukin 1 alpha gene polymorphism as a susceptibility factor in Alzheimer's disease and its influence on the extent of histopathological hallmark lesions of Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14(3):123-7. ,
Matsuda K, Tashiro K, Hayashi Y, Monji A, Yoshida I, Mitsuyama Y. Measurement of laminins in the cerebrospinal fluid obtained from patients with Alzheimer's disease and vascular dementia using a modified enzyme-linked immunosorbent assay. Dement Geriatr Cogn Disord. 2002;14(3):113-22.
Rodriguez G, Vitali P, De Leo C, De Carli F, Girtler N, Nobili F. Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology. 2002;46(1):49-56.
Kölsch H, Lütjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ML, Maier W, Heun R. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry. 2002;7(8):899-902. ,
Riazanskaia N, Lukiw WJ, Grigorenko A, Korovaitseva G, Dvoryanchikov G, Moliaka Y, Nicolaou M, Farrer L, Bazan NG, Rogaev E. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. Mol Psychiatry. 2002;7(8):891-8. , ,
Laws SM, Hone E, Taddei K, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry. 2002;7(8):886-90. ,
Sahlas DJ, Liberman A, Schipper HM. Role of heme oxygenase-1 in the biogenesis of corpora amylacea. Biogerontology. 2002;3(4):223-31.
Lee J, Chan SL, Mattson MP. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromolecular Med. 2002;2(1):29-45.
Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med. 2002;2(1):1-10.
Morys J, Bobek-Billewicz B, Dziewiatkowski J, Bidzan L, Ussorowska D, Narklewicz O. Changes in the volume of temporal lobe structures related to Alzheimer's type dementia. Folia Neuropathol. 2002;40(2):47-56.
Son GR, Therrien B, Whall A. Implicit memory and familiarity among elders with dementia. J Nurs Scholarsh. 2002;34(3):263-7.
Loew D. [In Process Citation] Wien Med Wochenschr. 2002;152(15-16):418-22.
Shadlen MF, McCormick WC, Larson EB. Research agenda for understanding Alzheimer disease in diverse populations: work group on cultural diversity, Alzheimer's association. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S96-S100.
Olin JT, Dagerman KS, Fox LS, Bowers B, Schneider LS. Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S82-5.
Whitfield KE. Challenges in cognitive assessment of African Americans in research on Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S80-1.
Valle R, Lee B. Research priorities in the evolving demographic landscape of Alzheimer disease and associated dementias. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S64-76.
Dilworth-Anderson P, Gibson BE. The cultural influence of values, norms, meanings, and perceptions in understanding dementia in ethnic minorities. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S56-63.
Powell AL. On issues pertinent to Alzheimer disease and cultural diversity. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S43-5.
Radebaugh TS, Ward-Robinson J. Cultural diversity and Alzheimer disease: introduction. Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S41-2.
Schimmöller F, Higaki JN, Cordell B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr Pharm Des. 2002;8(28):2521-31.
Block W, Träber F, Flacke S, Jessen F, Pohl C, Schild H. In-vivo proton MR-spectroscopy of the human brain: Assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration. Amino Acids. 2002;23(1-3):317-23.
Kochman A, Koska C, Metodiewa D. Submolecular adventures of brain tyrosine: what are we searching for now? Amino Acids. 2002;23(1-3):95-101.
Walker LC, Bian F, Callahan MJ, Lipinski WJ, Durham RA, LeVine H. Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key? Amino Acids. 2002;23(1-3):87-93.
Ingelsson M, Hyman BT. Disordered proteins in dementia. Ann Med. 2002;34(4):259-71.
Glöckner F, Meske V, Ohm T. Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience. 2002;114(4):1103.
Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2002;20(13):919-42.
Gätke MR, Viby-Mogensen J, Bundgaard JR. Rapid simultaneous genotyping of the frequent butyrylcholinesterase variants Asp70Gly and Ala539Thr with fluorescent hybridization probes. Scand J Clin Lab Invest. 2002;62(5):375-83.
Herrmann W, Knapp JP. Hyperhomocysteinemia: a new risk factor for degenerative diseases. Clin Lab. 2002;48(9-10):471-81.
Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002;7(4):199-206.
Shu SY, Wu YM, Bao XM, Wen ZB, Huang FH, Li SX, Fu QZ, Ning Q. A new area in the human brain associated with learning and memory: immunohistochemical and functional MRI analysis. Mol Psychiatry. 2002;7(9):1018-22.
Davis KL. NSAID and Alzheimer's disease; possible answers and new questions. Mol Psychiatry. 2002;7(9):925-6.
Gabryelewicz T, Religa D, Styczynska M, Peplonska B, Pfeffer A, Wasiak B, Luczywek E, Golebiowski M, Androsiuk W, Czyzewski K, Przekop I, Barcikowska M. Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein e genotype. Dement Geriatr Cogn Disord. 2002;14(4):208-12.
Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR. Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer's Disease. Dement Geriatr Cogn Disord. 2002;14(4):198-207.
Sjögren M, Wikkelsö C, Ostling S, Wallin A, Blennow K. Biological correlates of clinical subgroups of Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14(4):191-7. ,
Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal Fluid Phospho-Tau, Total Tau and beta-Amyloid(1-42) in the Differentiation between Alzheimer's Disease and Vascular Dementia. Dement Geriatr Cogn Disord. 2002;14(4):183-90. ,
Lin KN, Wang PN, Liu CY, Chen WT, Lee YC, Liu HC. Cutoff scores of the cognitive abilities screening instrument, chinese version in screening of dementia. Dement Geriatr Cogn Disord. 2002;14(4):176-82.
Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, O'Brien J, Perry RH, Ince PG, Edwardson JA, Morris CM. Clinical and neuropathological correlates of apolipoprotein e genotype in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;14(4):167-75.
Sipe JC, Lee P, Beutler E. Brain iron metabolism and neurodegenerative disorders. Dev Neurosci. 2002;24(2-3):188-96.
Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci. 2002;24(2-3):184-7.
Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115(1):201-11. ,
Debeir T, Marien M, Chopin P, Martel JC, Colpaert F, Raisman-Vozari R. Protective effects of the alpha(2)-adrenoceptor antagonist, dexefaroxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat. Neuroscience. 2002;115(1):41-53.
Blass JP. Glucose/mitochondria in neurological conditions. Int Rev Neurobiol. 2002;51:325-76.
Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs. 2002;16(12):811-24.
Rosen VM, Bergeson JL, Putnam K, Harwell A, Sunderland T. Working memory and apolipoprotein E: What's the connection? Neuropsychologia. 2002;40(13):2226-33.
Liberski PP, Gajdusek DC, Brown P. How do neurons degenerate in prion diseases or transmissible spongiform encephalopathies (TSEs): neuronal autophagy revisited. Acta Neurobiol Exp (Warsz). 2002;62(3):141-7.
Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2002;2(2):215-31.
Chan SL, Furukawa K, Mattson MP. Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 2002;2(2):167-96.
Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med. 2002;2(2):151-65.
Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2002;2(2):131-50.
Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med. 2002;2(2):89-99.
Swaab DF, Dubelaar EJ, Hofman MA, Scherder EJ, Van Someren EJ, Verwer RW. Brain aging and Alzheimer's disease; use it or lose it. Prog Brain Res. 2002;138:343-73.
Kesavapany S, Banner SJ, Lau KF, Shaw CE, Miller CC, Cooper JD, McLoughlin DM. Expression of the Fe65 adapter protein in adult and developing mouse brain. Neuroscience. 2002;115(3):951-60.
Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Gong CX. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience. 2002;115(3):829-37.
Hartonian I, Mufson EJ, de Lacalle S. Long-term plastic changes in galanin innervation in the rat basal forebrain. Neuroscience. 2002;115(3):787-95.
McRae TD, Schwam EM. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(6):i-iii; discussion iv-vi.
Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin. 2002;18(6):347-54.
Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, Kelley K, Dang A, Qing W, Teplow D, Pasinetti GM. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002;10(5-6):271-8.
Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med. 2002;34(5):357-79.
Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl. 2002;(62):327-36.
Solomon B, Frenkel D. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology. J Neural Transm Suppl. 2002;(62):321-5.
Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Tsujio I, Grundke-Iqbal I. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration. J Neural Transm Suppl. 2002;(62):309-19.
Münch G, Deuther-Conrad W, Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies? J Neural Transm Suppl. 2002;(62):303-7.
Permanne B, Adessi C, Fraga S, Frossard MJ, Saborio GP, Soto C. Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J Neural Transm Suppl. 2002;(62):293-301.
Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002;(62):277-85.
Ruether E, Alvarez XA, Rainer M, Moessler H. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002;(62):265-75.
Humpel C, Weis C. Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices. Implication in Alzheimer's disease? J Neural Transm Suppl. 2002;(62):253-63.
Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;(62):241-52.
Kesslak JP. Can estrogen play a significant role in the prevention of Alzheimer's disease? J Neural Transm Suppl. 2002;(62):227-39.
Winblad B, Möbius HJ, Stöffler A. Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope? J Neural Transm Suppl. 2002;(62):217-25.
Geerts H, Finkel L, Carr R, Spiros A. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. J Neural Transm Suppl. 2002;(62):203-16.
Fisher A, Brandeis R, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. Impact of muscarinic agonists for successful therapy of Alzheimer's disease. J Neural Transm Suppl. 2002;(62):189-202.
Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl. 2002;(62):181-7.
Flores-Flores C, Nissim A, Shochat S, Soreq H. Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. J Neural Transm Suppl. 2002;(62):165-79.
Windisch M, Hutter-Paier B, Schreiner E. Current drugs and future hopes in the treatment of Alzheimer's disease. J Neural Transm Suppl. 2002;(62):149-64.
Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Möbius HJ, Stöffler A. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl. 2002;(62):135-48.
Kurz A, Riemenschneider M, Drzezga A, Lautenschlager N. The role of biological markers in the early and differential diagnosis of Alzheimer's disease. J Neural Transm Suppl. 2002;(62):127-33.
Almkvist O, Axelman K, Basun H, Wahlund LO, Lannfelt L. Conversion from preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation. J Neural Transm Suppl. 2002;(62):117-25.
Smith G. Is mild cognitive impairment bridging the gap between normal aging and Alzheimer's disease? J Neural Transm Suppl. 2002;(62):97-104.
Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J. A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker? J Neural Transm Suppl. 2002;(62):87-95.
Arendt T. Dysregulation of neuronal differentiation and cell cycle control in Alzheimer's disease. J Neural Transm Suppl. 2002;(62):77-85.
Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. J Neural Transm Suppl. 2002;(62):69-75.
Jellinger KA. Vascular-ischemic dementia: an update. J Neural Transm Suppl. 2002;(62):1-23.
Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002 Jan;110(2):199-211. Abstract
Neely MD, Montine TJ. Csf lipoproteins and Alzheimer s disease. J Nutr Health Aging. 2002;6(6):383-91.
Austen B, Christodoulou G, Terry JE. Relation between Cholesterol levels, Statins and Alzheimer s Disease in the human population. J Nutr Health Aging. 2002;6(6):377-82.
Sarkar IN, Rindflesch TC. Discovering protein similarity using natural language processing. Proc AMIA Symp. 2002;:677-81.
Rawson RB. Regulated intramembrane proteolysis: from the endoplasmic reticulum to the nucleus. Essays Biochem. 2002;38:155-68.
Nunan J, Small DH. Proteolytic processing of the amyloid-beta protein precursor of Alzheimer's disease. Essays Biochem. 2002;38:37-49.
Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6(5):324-31.
Kim JM, Stewart R, Shin IS, Yoon JS. Low cholesterol, cognitive function and Alzheimer s disease in a community population with cognitive impairment. J Nutr Health Aging. 2002;6(5):320-3.
Levin-Allerhand JA, Lominska CE, Smith JD. Increased amyloid- levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging. 2002;6(5):315-9.
Rademakers R, Cruts M, Dermaut B, Sleegers K, Rosso SM, van den Broeck M, Backhovens H, Van Swieten J, van Duijn CM, van Broeckhoven C. Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval. Mol Psychiatry. 2002;7(10):1064-74.
Harris JR. In vitro fibrillogenesis of the amyloid beta(1-42) peptide: cholesterol potentiation and aspirin inhibition. Micron. 2002;33(7-8):609-26.
Perry G, Cash AD, Smith MA. Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol. 2002;2(3):120-123.
Mattson MP. Contributions of mitochondrial alterations, resulting from bad genes and a hostile environment, to the pathogenesis of Alzheimer's disease. Int Rev Neurobiol. 2002;53:387-409.
Swerdlow RH, Kish SJ. Mitochondria in Alzheimer's disease. Int Rev Neurobiol. 2002;53:341-85.
Spada RS, Cento RM, Proto C, Cosentino FI, Ferri R, Iero I, Lanuzza B, Mangiafico RA, Toscano G, Tripodi M, Lanzone A. Twenty-four-hour urinary cortisol levels in Alzheimer disease and in mild cognitive impairment. J Endocrinol Invest. 2002;25(10 Suppl):78-80.
Solerte SB, Cerutti N, Mirani M, Ceresini G, Giusti A, Ferrari E, Fioravanti M. Impairment of secretory pattern of IGF-I from lymphomononuclear cells in aging and dementia of the Alzheimer's and vascular type. J Endocrinol Invest. 2002;25(10 Suppl):47-50.
Szárics E, LaszTóczi B, Nyikos L, Barabás P, Kovács I, Skuban N, Nagy PI, Kökösi J, Takácsné NK, Kardos J. [EFfect of quinazolone-alkyl-carboxylic acid derivatives on the transmembrane Ca2+ ion flux mediated by AMPA receptors] Acta Pharm Hung. 2002;72(2):116-22.
Kurz A. Non-cognitive benefits of galantamine (Reminyl(R)) treatment in vascular dementia. Acta Neurol Scand Suppl. 2002;178:19-24.
Erkinjuntti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurol Scand Suppl. 2002;178:15-8.
Small GW. The role of neuroimaging in the diagnosis of vascular dementia. Acta Neurol Scand Suppl. 2002;178:10-4.
Román GC. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol Scand Suppl. 2002;178:6-9.
Charlton KE. Eating well: ageing gracefully! Asia Pac J Clin Nutr. 2002;11 Suppl 3:S607-17.
Saporito MS, Hudkins RL, Maroney AC. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem. 2002;40:23-62.
Allain H, Bentue-Ferrer D, Belliard S, Reymann JM, Djemaï M, Merienne M. [Mild Cognitive Impairment: potential therapeutics] Rev Neurol (Paris). 2002;158(10 Suppl):S35-40.
Sarazin M, Dubois B. [Mild Cognitive Impairment or pre-demential Alzheimer's disease?] Rev Neurol (Paris). 2002;158(10 Suppl):S30-4.
Laurent B, Thomas Antérion C. [Limits and uncertainties about the concept of MCI: contribution of neuropsychological approach] Rev Neurol (Paris). 2002;158(10 Suppl):S11-20.
Thompson SA, Hodges JR. Mild cognitive impairment: a clinically useful but currently ill-defined concept? Neurocase. 2002;8(6):405-10.
Chen H, Sun S, Mei Y, Liu C, Liu A, Tong E. The effect of beta-amyloid on neurons and the influence of glucocorticoid and age on such effect. J Tongji Med Univ. 2002;22(3):250-2.
Al-Khedhairy AA, Arfin M, Bin Dukhyil AA. Molecular cloning and sequencing of rabbit presenilin-1 cDNA fragment. Acta Biochim Pol. 2002;49(4):1013-7.
Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann Med. 2002;34(7-8):491-500.
Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002;63 Suppl 13:21-6.
Wierzba-Bobrowicz T, Gwiazda E, Kosno-Kruszewska E, Lewandowska E, Lechowicz W, Bertrand E, Szpak GM, Schmidt-Sidor B. Morphological analysis of active microglia--rod and ramified microglia in human brains affected by some neurological diseases (SSPE, Alzheimer's disease and Wilson's disease). Folia Neuropathol. 2002;40(3):125-31. ,
Behl C. Neuroprotective strategies in Alzheimer's disease. Adv Exp Med Biol. 2002;513:475-96.
Dechant G, Neumann H. Neurotrophins. Adv Exp Med Biol. 2002;513:303-34.
Schlattmann P. An introduction to statistical concepts for the analysis of EEG data and the planning of pharmaco-EEG trials. Methods Find Exp Clin Pharmacol. 2002;24 Suppl C:1-6.
Beelke M, Sannita WG. Cholinergic function and dysfunction in the visual system. Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:113-7.
Saletu B, Anderer P, Saletu-Zyhlarz GM, Pascual-Marqui RD. EEG topography and tomography in diagnosis and treatment of mental disorders: evidence for a key-lock principle. Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:97-106.
Mulert C, Jäger L, Pogarell O, Bussfeld P, Schmitt R, Juckel G, Hegerl U. Simultaneous ERP and event-related fMRI: focus on the time course of brain activity in target detection. Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:17-20.
Zhong ZG, Liu MC, Lai SL. [Effect of bushen yizhi recipe on neurotransmitter release in A beta segment neurotoxin induced NG108-15 cellular model of Alzheimer disease] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jan;22(1):50-3.
Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl. 2002;(63):91-109.
Clarfield AM. Teaching public health related to the elderly. Public Health Rev. 2002;30(1-4):271-6.
Kaltschmidt B, Heinrich M, Kaltschmidt C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromolecular Med. 2002;2(3):299-309.
Suram A, Rao KS, Latha KS, Viswamitra MA. First evidence to show the topological change of DNA from B-dNA to Z-DNA conformation in the hippocampus of Alzheimer's brain. Neuromolecular Med. 2002;2(3):289-97.
Valera E, Fernández-Salguero PM, Planells-Cases R, Messeguer A, Van Den Nest W, Carreño C, Ferrer-Montiel A, Merino JM. Neuroprotection against excitotoxicity by N-alkylglycines in rat hippocampal neurons. Neuromolecular Med. 2002;2(3):271-80.
Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr. 2002;14 Suppl 1:93-126.
Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91.
Corey-Bloom J. The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias. Int Psychogeriatr. 2002;14 Suppl 1:51-75.
Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr. 2002;14 Suppl 1:27-49.
Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psychogeriatr. 2002;14 Suppl 1:7-26.
Feldman H. Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far? Int Psychogeriatr. 2002;14 Suppl 1:3-5.
Youdim MB, Grünblatt E, Levites Y, Maor G, Mandel S. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotox Res. 2002 Nov-Dec;4(7-8):679-689.
Nilsberth C, Kostyszyn B, Luthman J. Changes in APP, PS1 and other factors related to Alzheimer's disease pathophysiology after trimethyltin-induced brain lesion in the rat. Neurotox Res. 2002 Nov-Dec;4(7-8):625-636.
Chen H, Sun S, Mei Y, Liu C, Liu A, Tong E. The effect of beta-amyloid on neurons and the influence of glucocorticoid and age on such effect. J Huazhong Univ Sci Technolog Med Sci. 2002;22(3):250-2.
Montgomery RJ, Marquis J, Schaefer JP, Kosloski K. Profiles of respite use. Home Health Care Serv Q. 2002;21(3-4):33-63.
Montgomery RJ, Kosloski K, Karner TX, Schaefer JP. Initial findings from the evaluation of the Alzheimer's Disease Demonstration Grants to States Program. Home Health Care Serv Q. 2002;21(3-4):5-32.
Guo Y, Shi X, Uchiyama H, Hasegawa A, Nakagawa Y, Tanaka M, Fukumoto I. A study on the rehabilitation of cognitive function and short-term memory in patients with Alzheimer's disease using transcutaneous electrical nerve stimulation. Front Med Biol Eng. 2002;11(4):237-47.
Mega MS. Differential diagnosis of dementia: clinical examination and laboratory assessment. Clin Cornerstone. 2002;4(6):53-65.
Dierks T, Jelic V. Monitoring of disease progression and therapeutic efficacy in Alzheimer's disease by electrophysiological indices. Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:75.
Some small-scale male enhancement side personal effects are the male private parts and heighten their intimate free energy,
ReplyDeleteanmale enhancement reviewis the help oneself you can get to interpret the merchandise's strength. All the same, all unexpended ingredients are wholly dependable as make for delectation in their sexual lives.
My web page - homepage
What's up, I log on to your blog like every week. Your humoristic style is witty, keep it up!
ReplyDeletemy site Cheap Ray Ban Sunglasses
Helpful info. Fortunаtе me І discovеred youг web ѕite by chancе,
ReplyDeleteand I am surрrised why thiѕ aсcident did not came аbout in adνance!
I booκmarκеd it.
Αlsο νіsіt my blog post ... AmericasCardRoom Bonus
Good day I am so glad І found your web site, Ι really
ReplyDeletefound you by miѕtake, while Ι wаѕ broωsing
on Google for something elsе, Anyways Ӏ am here now аnd would
just like to say κudοѕ for a fantаstic
pоst and a all гound thrіlling blοg (I also love the thеme/deѕign),
I don’t have time to browsе it all at the
mοment but I have booκmarked it and also included yоur RSS feeds,
ѕo when I have tіmе I ωіll be
back to гead a lot more, Pleasе dο kеep
uρ the eхcellent ωork.
Feel free to surf to mу ωeb pаge; Red Kings Poker Promotions
I have been browsing online greater than 3 hours these
ReplyDeletedays, but I by no means found any interesting
article like yours. It is beautiful worth sufficient for me.
In my opinion, if all website owners and bloggers made good content material as you
did, the net shall be a lot more useful than ever before.
Also visit my blog ... Beats By Dre Cheap
With the assistance of it has provided online followers
ReplyDeletea specific manual on the calendar of activities for both conventions
and exhibitions in exhibition centre and convention centre in Macau
for the complete year. Easiest Way to Increase HTC Desire HD
Battery Life. You get mobbed by wave after wave of troops,
seven or eight at a time, and it's quite easy to keep a kill streak going.
Here is my website; dragonvale free gems
Hi, I do think this is an excellent blog. I stumbledupon it ;) I
ReplyDeletewill come back once again since i have bookmarked it. Money
and freedom is the best way to change, may you be rich and continue
to guide other people.
Also visit my web blog Hermes Silk Scarf Sale
Greetings! Very useful advice in this particular article!
ReplyDeleteIt's the little changes which will make the largest changes.
Many thanks for sharing!
Also visit my web page; Beats By Dre
Hi, i think that i saw you visited my site so i came to “return the favor”.I'm
ReplyDeletetrying to find things to enhance my web site!I suppose its ok to use a few of your ideas!!\
my website Polo Ralph Lauren Scarf
Way cool! Some very valid points! I appreciate you penning this article
ReplyDeleteplus the rest of the site is extremely good.
Here is my site ... Louis Vuitton Scarf Cheap
I visited multiple web sites however the audio feature for audio songs current at this web site
ReplyDeleteis in fact superb.
Also visit my web page :: louis vuitton silk scarf
Hi there would you mind letting me know which hosting
ReplyDeletecompany you're utilizing? I've loaded your blog
in 3 different browsers and I must say this blog loads a
lot quicker then most. Can you recommend a good internet hosting provider at a fair price?
Thanks, I appreciate it!
My blog post - Dre Beats
Је souhaiterai vous dire quee c'est constamment
ReplyDeleteun plaisir de visiter votrdе site internet
Feel freе to vist my web blog :: vidéo porno gratuite
Εncore սn magnifique рoste : j'espère en discuter plus tard aѵec certsins de mes amis
ReplyDeleteAlso visit my web page; defonce hard
Sims at the party can also spray one another with nectar (similar to champagne) and
ReplyDeleteget each other soaking wet. All you need is to bear
Cost, testing expense and overall maintenance cost. Anytime they will need to call you or you may want to
reach them, you will be able to do so from your phone.
If you are travelling to more than one country in one journey, it
will be simpler to use your one international number, as opposed
to purchasing local SIM cards in each country.
Look into my page; เบอร์มงคล